Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

Study Warns on Venetoclax in Double-Hit Lymphoma



(MedPage Today) — Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial showed.
Median…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments